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ABSTRACT 
Anaplasia may be identified in a subset of tumors with a presumed pilocytic astrocytoma (PA) 
component or piloid features, which may be associated with aggressive behavior, but the 
biologic basis of this change remains unclear. Fifty-seven resections from 36 patients (23 M, 13 
F, mean age 32 years, range 3-75) were included. A clinical diagnosis of NF1 was present in 8 
(22%).  Alternative lengthening of telomeres (ALT) was assessed by telomere-specific FISH 
and/or CISH. A combination of immunohistochemistry, DNA sequencing and FISH were used to 
study BRAF, ATRX, CDKN2A/p16, mutant IDH1 p.R132H and H3-K27M proteins. ALT was 
present in 25 (69%) cases and ATRX loss in 20 (57%), mostly in the expected association of 
ALT+/ATRX- (20/24, 83%) or ALT-/ATRX+ (11/11, 100%). BRAF duplication was present in 8 
(of 26) (31%). H3-K27M was present in 5 of 32 (16%) cases, all with concurrent ATRX loss and 
ALT. ALT was also present in 9 (of 11) cases in the benign PA precursor, 7 of which also had 
ATRX loss in both the precursor and the anaplastic tumor. In a single pediatric case, ALT and 
ATRX loss developed in the anaplastic component only, and in another adult case, ALT was 
present in the PA-A component only, but ATRX was not tested. Features associated with worse 
prognosis included subtotal resection, adult vs. pediatric, presence of a PA precursor preceding 
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a diagnosis of anaplasia, necrosis, presence of ALT and ATRX expression loss. ALT and ATRX 
loss, as well as alterations involving the MAPK pathway, are frequent in PA with anaplasia at 
the time of development of anaplasia or in their precursors. Additionally, a small subset of PA 
with anaplasia have H3-K27M mutations. These findings further support the concept that PA 
with anaplasia is a neoplasm with heterogeneous genetic features and alterations typical of both 
PA and diffuse gliomas. 
Key Words: Pilocytic astrocytoma, Glioma, H3-K27M, ATRX, Alternative lengthening of 
telomeres. 
INTRODUCTION 
Pilocytic astrocytoma (PA) represents the most frequent primary brain tumor in children, and 
accounts for 15.5 % of CNS tumors in patients in the 0-19 age range in the United States (30). 
These tumors have a predilection for the cerebellum, but may also develop in the optic 
pathways, cerebrum, brainstem or spinal cord. PAs are well differentiated astrocytomas, 
characterized at the histologic level by bipolar astrocytes and a biphasic architecture in classic 
cases, including compact areas with Rosenthal fibers alternating with loose areas with myxoid 
stroma, microcysts and variable numbers of eosinophilic granular bodies. Glomeruloid 
microvasculature is frequent,but has no prognostic significance when compared with diffuse 
gliomas. Bland necrosis is another feature that may be present in up to 10% of cases, but is 
also not associated with a worse outcome(11). In general, mitotic activity is low to altogether 
absent. 
Our knowledge of the underlying biologic features of PA has expanded in the past decade 
(reviewed in(5)). Numerous studies have demonstrated that a tandem duplication involving the 
kinase domain of BRAF and leading to a novel fusion (KIAA1549-BRAF) is present in most 
sporadic PA (2, 10, 18, 33, 42), while NF1 gene inactivation is the key feature of tumors 
developing in NF1 patients (12). Molecular alterations in single genes that lead to MAPK 
pathway activation have emerged as a universal finding in PA, occurring in 100% of tumors 
through a variety of mechanisms (16). Other signaling pathways are active and participate in PA 
biology, particularly mTOR, which is being explored as a therapeutic target (15, 19). 
PA is assigned a WHO grade I designation given its slow growth potential, long patient survival 
and potential for cure when totally resected. However, a small subset of PA develop anaplastic 
changes either de novo or in the setting of prior irradiation (8, 48). Grading criteria for these 
tumors remain to be defined (6), although working criteria on a prior series of 34 cases included 
brisk mitotic activity with or without necrosis (38). These findings were associated with a worse 
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prognosis, akin to diffuse gliomas when compared to historic cohorts. The molecular alterations 
associated with PA with anaplasia are currently being identified. We have previously 
documented frequent PI3K/mTOR activation in these tumors, in addition to MAPK activation and 
deletions involving PTEN and CDKN2A (37). A recent study by Reinhardt et al. has identified a 
separate molecular methylation class corresponding to a subset of PA with anaplasia, which is 
also characterized by frequent CDKN2A and alpha thalassemia/mental retardation syndrome X-
linked (ATRX) alterations (36). In the current study, we explore the frequency of ATRX and H3-
K27M alterations, as well as the presence of alternative lengthening of telomeres (ALT) for the 
first time, in PA with anaplasia based on strict histopathologic criteria. 
 
MATERIALS AND METHODS 
Patients and Samples 
Clinical and demographic characteristics, including NF1 status, were abstracted from 
retrospective chart review and consult letters. A total of 36 patients (23 M, 13 F) were included 
in the study.  A total of 57 pathologic specimens were reviewed, including 36 primary resections 
of PA-A, 16 biopsies representing PA preceding a diagnosis of anaplasia, and 5 for 
recurrences/second biopsies after anaplasia. The mean age of diagnosis of anaplasia was 32 
years (range 3-75). Patients included 17 cases reported in two prior studies (37, 38) but with 
updated clinical follow-up. Cerebellum/posterior fossa location was most common (n=21), 
followed by supratentorial hemispheric (n=7), supratentorial intraventricular (n=3), tectum/pineal 
(n=3), and spinal cord (n=2). Demographics and basic clinical features of the cohort studied are 
presented in Table 1. Cases were included in the study if they satisfied strict histologic criteria 
for anaplasia as previously described (38). In brief, all tumors were characterized by brisk 
mitotic activity (at least 5 mitoses per 10 high power fields), as well as hypercellularity and 
moderate-to-severe cytologic atypia. Necrosis was recorded as present or absent. Anaplasia 
was designated as focal when present in a single low power (X20) field, otherwise it was 
interpreted as diffuse. To exclude the possibility of an infiltrating glioma, particularly 
glioblastoma IDH wildtype, specific morphologic features of a low grade, circumscribed PA 
precursor were required in addition to anaplasia, including compact piloid morphology, 
Rosenthal fibers and/or eosinophilic granular bodies. It must be noted that none of these 
features in isolation are specific for PA, since infiltrating gliomas may have any one of these. 
Tumors with overt tissue infiltration or high grade features in the precursor were excluded. 
Morphologic mimics of PA (e.g. ganglioglioma, pleomorphic xanthoastrocytoma, rosette forming 
glioneuronal tumors) were also excluded. In addition, a group of 163 PA or low grade gliomas 
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with PA features were studied as a control using telomere-specific FISH or CISH, as well as 
ATRX and H3-K27M immunohistochemistry, obtained from TMA (n=116) or whole sections 
(n=47) evaluated by one of us (FJR) using the same conditions as the study cases. All studies 
were performed following standard ethical guidelines under Institutional Review Board (IRB) 
approval. 
 
Telomere-specific FISH and CISH 
ALT status was interpreted using previously published criteria, and was characterized by the 
presence of distinct large signals, in FISH or CISH. Cases were considered ALT-positive when 
foci defined as >10 fold brighter (in telomere FISH) or larger (in telomere CISH) compared to the 
average signal of telomeres in stromal cells was present in >1% of cancer nuclei (13, 14, 39). 
Additional details are given in our prior publications.  ALT status was tested by FISH only in 23 
cases, CISH only in 4 cases, and by both methods in 9 cases. Whole slides (n=23) or tissue 
microarrays (n=13) were used.    
Telomere-specific FISH was performed as previously described (13, 14, 39). In brief, 
deparaffinized slides were hydrated, steamed for 25 minutes in citrate buffer (Vector 
Laboratories), dehydrated, and hybridized with a Cy3-labeled peptide nucleic acid (PNA) probe 
complementary to the mammalian telomere repeat sequence [(N-terminus to C-terminus) 
CCCTAACCCTAACCCTAA]. As a positive control for hybridization efficiency, an Alexa Fluor-
488–labeled PNA probe specific to human centromeric DNA repeats 
(ATTCGTTGGAAACGGGA; CENP-B–binding sequence) was included in the hybridization 
solution. Following post-hybridization washes, the slides were counterstained with DAPI.  
Telomere-specific CISH was performed as previously described (39). Briefly, deparaffinized 
slides were hydrated, steamed for 25 minutes in citrate buffer, dehydrated, and hybridized with 
a Cy3-labeled PNA probe (described above). Sections were blocked against endogenous 
peroxidase activity with Dual Endogenous Enzyme-Blocking Agent (Dako) for 10 minutes, 
incubated with a monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500) for 1 hour at 
room temperature, then incubated with an anti-mouse secondary antibody (Leica Microsystems) 
for 30 minutes, and detected with 3,30-diaminobenzidine (Sigma-Aldrich) after 10 minutes. 
Finally, sections were counterstained with hematoxylin, rehydrated, and mounted. 
 
BRAF and CDKN2A Alterations 
BRAF duplication or KIAA1549:BRAF fusion and CDKN2A status was retrospectively obtained 
from a prior study (n=14)(37), as well as through diagnostic evaluation as part of the clinical 
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workup through next generation sequencing (n=2), or using a BRAF (7q34) rearrangement by 
FISH assay employing a 186kb red probe centromeric(3’) to the BRAF gene and two 
overlapping green probes telomeric (5’) to BRAF and spanning 335kb (Empire Genomics).  
In a subset of cases (n=12), FISH for BRAF duplication was systematically performed as 
a laboratory developed test that is clinically validated in a CAP/CLIA certified laboratory at St 
Jude Children’s Research Hospital.  The design includes a target probe at the BRAF locus on 
7q34 and a control Probe at 7p11.2.  This design demonstrates a “doublet” pattern in the setting 
of the KIAA1549-BRAF fusion which is presumed to be related to the tandem duplication of the 
BRAF gene during the generation of the fusion (18). The dual-color duplication probe set for 
BRAF was derived from BAC clones RP11-96I22 with 7p controls RP11-251I15 and RP11-
746C13 (BACPAC Resources, Oakland, CA). Probes were labeled with either AlexaFluor-488 
or AlexaFluor-555 fluorochromes and nuclei were counterstained with DAPI (200ng/ml)(Vector 
Labs) for viewing on an Olympus BX51 fluorescence microscope equipped with a 100 watt 
mercury lamp; FITC, Rhodamine, and DAPI filters; 100X PlanApo (1.40) oil objective; and a Jai 
CV digital camera.  Images were captured and processed using the Cytovision v7.3 software 
from Leica Biosystems (Richmond, IL). 
CDKN2A homozygous deletion was tested using a commercially available locus-specific probe 
(9p21, Abbott Molecular/Vysis) and centromere 9 (CEP9) control probe. Deletion was defined 
as a ratio of LSI to control probe of <0.8, and homozygous deletion as loss of both CDKN2A 
copies in at least 10% of neoplastic cells, with preserved centromere signals in the same 
neoplastic cells and both target and centromere signals in non-neoplastic internal controls. 
 
Immunohistochemistry 
Immunohistochemical slides performed as part of the clinical evaluation were reviewed. In 
missing or equivocal cases, immunohistochemical studies were systematically performed using 
the following antibodies: ATRX (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-
Aldrich), H3-K27M (Rabbit polyclonal, Dilution 1:400, catalog# ABE419, Millipore Sigma), p16 
(CINtec®, prediluted, catalog# 705-4713, Roche), IDH1-R132H (Clone H09, 1:100 dilution, 
catalog# ,Dianova), p53 (clone BP53-11, prediluted, catalog# 760-2542, Ventana). 
Immunostaining was performed on automated instruments (BenchMark, Ventana Medical 
Systems, Tucson, AZ, USA). The immunohistochemical protocol included deparaffinization, 
hydration, antigen retrieval, primary antibody incubation, and detection and visualization as per 
manufacturer’s instructions. Immunohistochemistry for DAXX (Rabbit polyclonal, 1:100 dilution, 
catalog# HPA008736, Atlas Antibodies) was performed manually. Sections were incubated with 
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primary antibody for 2 hours at room temperature followed by secondary antibody (Leica 
Microsystems) for 30 min and detected with 3,30-diaminobenzidine (Sigma-Aldrich) after 10 
min. For ATRX and DAXX, preserved immunoreactivity in internal non-neoplastic cell 
components was required for valid interpretation in all cases. 
 
Targeted Next Generation Sequencing 
Next Generation Sequencing (NGS) studies were performed by various methods at referring 
institutions as part of the clinical workup (n=4). In two additional H3-K27M positive cases and 
one H3-K27M negative case, NGS was performed at Johns Hopkins as previously described 
(32). Briefly, DNA libraries were prepared using Agilent SureSelect-XT reagents (Agilent 
Technologies, Inc., Santa Clara, CA) with genomic regions of interest captured by means of an 
Agilent custom-designed bait set covering the full coding regions of 644 cancer-associated 
genes (exon 1 is poorly covered for some genes). 
 
Statistics 
Variables were described using proportions, ranges, means and medians as appropriate. 
Proportions were compared using Chi-Square or Fisher’s exact tests as appropriate, while 
Student’s t-test or Wilcoxon rank sum was used to compare continuous variables between 
groups of interest. Survival rates were analyzed using Kaplan–Meier curves and the log-rank 
test. Overall survival was calculated from the time of diagnosis of anaplasia to death. 
Recurrence free/progression free survival was calculated from the time of diagnosis of 
anaplasia to the first evidence of tumor growth per clinical record, or time of death. Patients 
were jointly classified by the presence of necrosis and ALT status and by the presence of 
necrosis and ATRX expression. Cox proportional hazards regression was used to estimate the 
age-adjusted relative hazard (HR) and 95% confidence interval (CI) of overall survival and of 
recurrence free/progression free survival for each joint category, with necrosis-free/ALT-
negative patients (or loss of ATRX expression) as the reference, and for the joint categories 
modeled as an ordinal variable to estimate a p-trend. JMP v10 or SAS v9.4 software (SAS 
Institute) were used for statistical analyses. All analyses were 2-sided with p values <0.05 
considered statistically significant. 
 
RESULTS 
Alternative lengthening of telomeres and ATRX loss are frequent in pilocytic astrocytoma 
with anaplasia 
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Anaplastic changes were predominantly diffuse (n=32) but focal in 4 cases. ALT was present in 
25/36 (69%) cases and ATRX loss in 20/35 (57%), mostly in the expected pattern ALT+/ATRX- 
(20/24, 83%) or ALT-/ATRX+ (11/11, 100%) (Figures 1-4). ATRX loss was diffuse in 17 (of 20) 
cases and partial (i.e. clearly involving a subset of tumor cells) in the 3 remaining cases. 
Discrepant results included ALT+/ATRX+ in 4 cases. DAXX immunohistochemistry was 
performed in two of these ALT+/ATRX+ cases and demonstrated preserved immunoreactivity in 
both. Eleven patients were strictly pediatric (<18 years old) at diagnosis with an age range 3-17 
years. Four (36%) of these pediatric tumors had ALT and concurrent ATRX loss. In contrast, 
only 5/88 (5%) conventional PA or low grade gliomas with PA features had ALT, all of which 
represented recurrences or tumors that behaved aggressively, and only 1 of these had 
concurrent ATRX loss. Only 4/154 (2.5%) PA or low grade gliomas with PA features had ATRX 
expression loss (1 partial, 3 complete).  
BRAF duplications/fusions were identified in 8 (of 26)(31%) cases tested, including one case 
tested by a rearrangement probe set with ATRX loss and ALT. BRAF p.V600E was not 
encountered in 31 cases tested. However, rare mutations involving the MAPK pathway were 
identified in 3 cases: one case had a BRAF p.D594G, NF1 p.Y1545, NF1 p.K1440 mutations 
and concurrent ALT, but demonstrated no ATRX loss or ATRX mutation by NGS. One case had 
BRAF p.L64I and NF1 p.L2398M mutations as well as ALT and ATRX p.S856del, and another 
case had a KRAS p.Q61H and two ATRX mutations (Table 1). 
CDKN2A homozygous deletions were identified in 3 (of 18; 17%) cases tested by FISH 
(n=12), NGS (n=6) or by both FISH and NGS (n=1). P16 protein loss was present in 13 (of 14) 
cases tested, being complete in 7 and partial in 6 cases. Strong p53 immunolabeling, defined as 
strong (3+) intensity present in >50% of neoplastic cells, was identified in 6 (of 17; 35%), while 
all cases tested for mutant IDH1 (R132H) by immunohistochemistry (n=32) were negative. Eight 
cases studied by sequencing showed no IDH1 or IDH2 hotspot mutations. Immunophenotypic 
and molecular alterations are summarized in Table 2. 
 
Histologic precursors to pilocytic astrocytoma with anaplasia 
PA precursors for PA-A (i.e. pathologically confirmed PAs preceding a diagnosis in PA-A) were 
present in 15 cases, with an interval for anaplastic progression ranging from 5 to 307 months 
(mean 67 months). In the remaining 21 cases anaplastic changes were present at first 
diagnosis. Treatments for the precursor PA tumors included observation (n=5), irradiation only 
(n=6) and irradiation and chemotherapy (n=3). Treatment information was unknown in one case. 
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ALT and/or ATRX expression was also tested in the low grade/PA component in14 cases where 
the PA precursor component was available for testing, including samples preceding a diagnosis 
of PA-A (n=6) or present in the same specimen as the anaplastic component (n=8). ALT was 
present in 9/14 and ATRX loss in 7/11. 
When looking at ALT-positive PA-A, ALT was also present in 9 (of 11) PA precursors, 7 
of which also demonstrated ATRX loss in both the precursor and the anaplastic tumor. In a 
single case (case 1), ALT and ATRX loss developed in the anaplastic component only, and 
were absent in the PA precursor two years prior and the persistent benign PA component 
present concurrently with the anaplastic areas (Figure 2).  In another case (case 24), ALT was 
present in the PA-A, but not in the concurrent low grade precursor, although ATRX was not 
tested. In no cases was ALT present in the low grade PA precursor only. 
 
A subset of pilocytic astrocytoma with anaplasia have H3-K27M mutations 
H3-K27M was present in 5 of 32 (16%) cases tested (Table 1). This subgroup included three 
males and 2 females, with a median age of 36 (range 4-53). Anatomic locations of the H3-K27M 
mutant cases included the posterior fossa/cerebellum (n=3), the spinal cord (n=1), and the third 
ventricle (n=1). All demonstrated ATRX loss and ALT, and 1 (of 5) had a concurrent BRAF 
duplication (Figure 3). This patient also had tissue available from a low grade pilocytic 
precursor resected two years prior (case 9). ATRX loss and the H3-K27M mutation were 
identified in this precursor, as well, although the proportion of H3-K27M positive cells was lower 
(Figure 3). In one additional H3-K27M positive case, the alteration was also present in the 
concurrent presumed PA precursor. Another case (case 35) had a H3F3A p.A115G mutation. In 
contrast only 1/145 (0.6%) conventional PA or low grade gliomas with PA features was H3-
K27M positive. Interestingly, this was a recurrent tumor. 
In three of these 5 PA-A with available material, NGS studies confirmed H3F3A p.K27M 
and ATRX mutations, as well as other alterations (Table 1). Three (of 5) patients with H3-K27M 
mutations died 4, 25, and 55 months after diagnosis. The two remaining patients are alive 
without evidence of disease at 6 and 39 months after diagnosis. 
 
NF1-associated pilocytic astrocytoma with anaplasia 
A clinical diagnosis of NF1 was present in 8 cases (22%), 4 (50%) of which were ALT-positive 
and 5 (63%) displayed ATRX loss (Figure 4). Anatomic locations included the cerebellum (n=3), 
hemispheres (n=4) and pineal region (n=1).  Four additional patients not satisfying clinical 
criteria for NF1 had NF1 mutations identified by NGS, including the single case with BRAF 
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p.D594G. All relevant alterations tested in PA-A and precusors, are summarized by case and 
group in Figure 5. 
 
Pilocytic astrocytoma with anaplasia are associated with a poor outcome 
Clinical follow-up was available in 31 patients. Of this cohort, 19 patients died during the follow-
up period, with a median overall survival of 13 months (range 2-55 months) after the diagnosis 
of anaplasia. Recurrence/progression was documented in 21 patients, with a median 
recurrence/progression-free survival of 9.8 months. Interval to recurrence/progression in all 
cases from the time of the primary pathologic diagnosis (whether anaplasia was present or not) 
was 48 months (range 2-317). Clinicopathologic and molecular features associated with a worse 
overall survival included subtotal vs. gross total resection (p=0.01), adult vs. pediatric patients 
(p=0.03), presence of a PA precursor preceding PA-A vs. de novo anaplastic changes (p=0.02), 
presence of necrosis (p=0.009), presence of ALT (p=0.03) and ATRX loss (p=0.04) (Figure 6, 
Table 3). There was a trend for worse overall survival in patients with a history of irradiation 
(p=0.06) that did not reach statistical significance. Features not associated with overall survival 
included BRAF duplication/fusion, presence of H3-K27M mutant protein, clinical NF1 diagnosis, 
supratentorial vs. infratentorial location, and sex (p>0.05). Clinicopathologic features associated 
with a decreased recurrence/progression-free survival included subtotal vs. gross total resection 
(p=0.0005), ALT+ vs. ALT- tumors (p=0.02), ATRX loss (p=0.03) and necrosis (p=0.02) (Figure 
6). Features not associated with recurrence/progression-free survival included BRAF 
duplication/fusion, presence of H3-K27M mutant protein, clinical NF1 diagnosis, supratentorial 
vs. infratentorial location, presence of a PA precursor preceding a diagnosis of PA-A vs. de 
novo anaplastic changes, adult vs. pediatric patients, prior irradiation, and sex (p>0.05). Finally, 
compared to patients with necrosis-free/ALT-negative tumors, patients with necrosis-free/ALT-
positive tumors had no difference in survival (HR=0.97; 95% CI: 0.17-5.42). In contrast, patients 
with necrotic/ALT-negative tumors had a non-significant higher risk of death (HR=1.95; 95% CI: 
0.32-11.83); whereas, patients with necrotic/ALT-positive tumors had a significantly higher risk 
of death (HR=6.52; 95% CI: 1.28-33.19; p-trend=0.005). Results were similar when recurrence 
free/progression free survival was modeled as the outcome, and when ATRX expression, 
instead of ALT status, was used in the joint categories. Given the small sample size and 
therefore imprecision of these estimates, findings should be interpreted with caution. 
Nonetheless, these findings strongly support further study of ALT and ATRX expression in this 
neoplasm. 
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DISCUSSION 
The concept of PA-A historically has been controversial, but PA-A is emerging as a brain tumor 
category of interest. Current evidence suggests a worse clinical outcome than conventional PA, 
but better than high grade astrocytomas, particularly those that are IDH wildtype (36, 38). 
Activation of the MAPK and PI3K/mTOR pathway, as well as CDKN2A alterations have been 
previously associated with anaplasia in PA (36, 37). More recently, the co-occurrence of BRAF 
p.V600E and CDKN2A mutations have been associated with worse outcome in pediatric low 
grade glioma (23). Even though CDKN2A alterations were identified in our cohort, BRAF 
p.V600E was uniformly absent. 
Prior studies have demonstrated a strong association of alterations in ATRX or death 
domain-associated protein (DAXX) genes with the alternative lengthening of telomeres (ALT) 
phenotype in several cancer subtypes, particularly gliomas, pancreatic neuroendocrine tumors 
and certain sarcomas (13). However, in ALT-positive gliomas, alterations involve predominantly 
ATRX. ATRX and DAXX are chromatin remodeling proteins that work at repetitive regions, 
including telomeres, to incorporate H3.3 into heterochromatin. ATRX mutations and ALT are 
also associated with specific molecular subgroups of brain tumors, particularly a subset of 
pediatric glioblastoma (41) and IDH mutant diffuse astrocytomas (3, 28). Specifically, previous 
studies have demonstrated an almost perfect concordance between ATRX mutations in high 
grade gliomas with ALT (13, 28). The vast majority of ATRX mutations occurring in association 
with ALT are inactivating and associated with nuclear protein loss as demonstrated by 
immunohistochemistry, which serves as a useful surrogate marker. ATRX protein loss is specific 
to neoplastic cells, since internal non-neoplastic brain components preserve ATRX 
immunoreactivity within tumors. More recently, we demonstrated that ATRX loss and ALT are 
frequent features of diffuse and high grade astrocytomas developing in patients with NF1 (39). 
This is of particular interest, since approximately 25% of PA-A develop in patients with a clinical 
diagnosis of NF1 (38). Interestingly, in our study, additional tumors demonstrated NF1 gene 
mutations in the absence of the absence of clinical NF1, and when combining these groups, the 
frequency of NF1 altered tumors reaches 33%. 
The current study expands the glioma subgroups that are dependent on ALT for telomere 
maintenance for the first time to also include PA-A. We identified ALT in 69% and ATRX protein 
loss in 55% of PA-A. ATRX mutations were also identified in 45% in the study of Reinhardt et al, 
where a distinct molecular class was discovered (36), and referred to as anaplastic astrocytoma 
with piloid features. Other similarities with this study included an absence of IDH mutations. In 
the study by Reinhardt et al. the most frequent alteration was CDKN2A deletion (80%). We 
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found homozygous deletions in CDKN2A in 20% of cases tested, but more cases with p16 loss 
by immunohistochemistry, suggesting inactivation in 67%. The lower frequency of CDKN2A 
deletions in our study may be in part explained by differences in methods, since most cases 
were tested for CDKN2A deletion by FISH rather than by higher resolution techniques such as 
next generation sequencing. The frequency of p16 loss by immunohistochemistry was higher in 
our cohort, and p16 loss by immunohistochemistry has been found to be associated with shorter 
overall survival in PA (35). However, Loss of p16 expression by IHC is not the most optimal 
marker to assess CDKN2A inactivation, since p16 expression is very low in non-neoplastic cells 
and it is difficult to confidently determine loss of expression in tumor cells.  
In our study, the concordance between ALT and ATRX expression was somewhat lower 
than expected based on our prior experience and the literature. Several possibilities may 
explain these observations. First, in some instances loss of ATRX function may occur (e.g. point 
mutations) while preserving protein levels and thereby leading to a normal 
immunohistochemistry result. Additionally, it is possible that alterations in DAXX or other 
heretofore unidentified ALT suppressors may occur in these cases. We were able to stain for 
DAXX in two ALT+ cases and expression was preserved in both. Additionally, no DAXX 
mutations were identified in the study by Reinhardt et al., suggesting that other genetic hits may 
explain anaplasia in PA with ALT lacking ATRX alterations. 
The presence of H3-K27M mutations defines the diffuse midline glioma H3-K27M 
mutant, a WHO grade IV category that has been included in the 2016 WHO Classification 
update (26). This alteration is frequent in diffuse gliomas that develop in midline anatomical 
structures, particularly brainstem and spinal cord and are in general associated with poor clinical 
outcome irrespective of histologic grade (20, 44, 46, 49). However, recent studies have 
identified these mutations in other histologic subtypes, where the outcome may be relatively 
more favorable (29, 40). These include circumscribed gliomas, that may also have other known 
drivers including BRAF p.V600E or NF1 mutations (34). Additionally, recent studies suggest that 
H3-K27M may develop subclonally, presumably during tumor progression rather than an 
initiating event (24).Given these observations, in a recent statement cIMPACT-NOW (the 
Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy—Not 
Official WHO) recommends that the category of diffuse midline glioma, H3-K27M mutant, be 
only applied to tumors that share all those properties encompassing its name (i.e. they are 
diffuse, midline, glial and have the H3-K27M mutation), excluding circumscribed gliomas and 
others (25). 
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In the current study, we found H3-K27M mutant protein in 5 cases, which is a higher 
frequency compared with the study of Reinhardt et al, where H3-K27M mutant protein was 
detected in 1 (of 47) cases (36). Of interest, all of the H3-K27M mutant cases in our study also 
had ALT and ATRX loss, which was confirmed by sequencing in the three cases undergoing 
further testing. This is intriguing, since ATRX mutations are most often associated with H3F3A 
p.G34 mutations (9, 22), occurring in most of the latter, but in only 15-20% of H3-K27M mutant 
tumors (9, 20). This suggests that ALT is an important biologic feature of PA-A, irrespective of 
the underlying oncogenic drivers (e.g. BRAF, NF1 or H3-K27M). Interestingly, we encountered a 
single case with BRAF duplication and H3-K27M. Concurrent BRAF p.V600E and H3-K27M 
mutations have been rarely reported (31, 44), but BRAF duplications must be even less 
frequent. It must be noted that prior studies have not found either ATRX/H3-K27M alterations or 
ALT in conventional PA, with only rare exceptions (9, 14, 29). One case in our study had a 
H3F3A p.A115G mutation, which has been identified rarely in squamous cell carcinoma of the 
upper aerodigestive tract (27) (https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=3930660), 
but not in brain tumors to our knowledge, and therefore its clinical significance in glioma is 
unclear.  
The current study expands our knowledge regarding the molecular alterations 
associated with PA-A. However, it is still unclear what is the precise sequence of events leading 
to anaplasia in these tumors. The mechanisms are likely heterogeneous, but alterations in 
MAPK pathway components or H3 histone (H3-K27M) appear to be early drivers. The majority 
of MAPK pathway alterations involve NF1 loss or BRAF activation, as well as FGFR1 in some 
instances (1, 36). In most instances, ATRX alterations and ALT appear to develop early, but at 
least in two cases in our current study they were identified only in the anaplastic component 
suggesting that they play an important role in anaplastic change. One important conclusion of 
our study is that ALT, H3-K27M and ATRX loss may identify PAs that are most likely to behave 
aggressively or develop anaplastic change, since these alterations were present in most 
precursors tested, when present in PA-A. Furthermore, although these alterations were rare in a 
control group, with only 5% of PA showing ALT and <1% H3-K27M, these tumors were either 
recurrent or clinically aggressive PA.  
ATRX loss appears to have numerous effects and leads to substantial epigenomic 
changes that have cell context dependent oncogenic effects (7). However, not all tumors 
demonstrate ATRX alterations and ALT, and therefore other mediators of anaplasia remain to 
be discovered. Additionally, DNA methylation based classification is emerging as a powerful tool 
to classify brain tumors including rare entities (4). In our study, genetic and phenotypic features 
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associated with PA-A were present in most concurrent or earlier conventional PA precursors, so 
it is possible that they also share methylation profiles. However, methylation studies in the future 
could play a role in identifying early those rare PA that undergo anaplasia and PA-A associated 
changes secondarily during the process of malignant progression, as our index case (case 1 
and Figure 2).  
Our current study confirms prior observations that PA-A is a malignant neoplasm with a 
high potential for recurrence and death (36, 38). Features that were associated with a worse 
outcome in our study included subtotal resection (vs. complete), adult (>17 years) age at 
diagnosis of anaplasia, the presence of a PA precursor preceding an PA-A diagnosis, necrosis 
during histologic examination, ALT-positive and ATRX loss of expression. Some of these 
associations are expected in part, since PA is predominantly a surgical disease and the extent 
of resection historically is one of the most important prognostic factors. PA-A is also more 
frequent in adult patients, and PA developing in adult patients tend to be more aggressive at the 
biologic and clinical levels (17, 45, 47). The association of a PA precursor preceding anaplasia 
with a worse outcome is intriguing and could be explained by several factors. It is possible that 
prior surgery or irradiation have an impact of outcome. Alternatively, a PA precursor not 
satisfying histologic criteria for anaplasia may still be more biologically aggressive, and affect 
overall prognosis starting at the time of diagnosis. 
 A novel feature of our study is that we found ALT and ATRX loss to be associated with 
worse overall and recurrence/progression-free survival. This suggests that ALT-positive/ATRX-
negative PA-A is a distinct category with important prognostic implications. Given the 
association of ALT with different gliomas subsets, its specific role in prognosis appears to be 
context dependent, since it is also a feature of IDH-mutant astrocytomas with ATRX loss, which 
have a better prognosis than IDH wildtype tumors. Interestingly, primary pancreatic 
neuroendocrine tumors with ALT and ATRX/DAXX loss are associated with a worse clinical 
outcome (21, 43).  
In summary, ALT, ATRX loss and alterations involving components of the MAPK 
pathway are frequent in PA-A at the time of development of anaplasia or their precursors. 
Additionally, a small subset of PA-A have H3-K27M mutations. These findings further support 
the concept that PA-A is a neoplasm with heterogeneous genetic features and putative drivers 
and combined alterations typical of PA and diffuse gliomas. 
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FIGURE LEGENDS 
Figure 1: Pilocytic astrocytoma with anaplasia (PA-A) with concurrent BRAF duplication 
and ALT. PA-A developing in the spinal cord demonstrating Rosenthal fibers and frequent 
mitotic activity (A). Spinal cord PA-A with well-differentiated pilocytic areas, containing loose 
microcystic areas with eosinophilic granular bodies (B). Concurrent areas of anaplasia were 
characterized by hypercellularity, brisk mitotic activity and pseudopalisading necrosis (C). The 
immunoprofile included expression of OLIG2 (D), p16 loss (E), high ki67 labeling index (F), and 
ATRX loss (G). Ultrabright telomere FISH signals consistent with ALT (arrow) (H) and BRAF 
duplication (I) were also present. 
 
Figure 2: Pilocytic astrocytoma with anaplasia (PA-A) with ATRX loss and ALT in the 
anaplastic component only (case 1). The tumor at first resection was hypocellular, composed 
of piloid areas with oligodendroglial-like cells and Rosenthal fibers (A). The same component 
was present in a subsequent resection, in the absence of radiotherapy (C), but in addition 
contained sharply demarcated hypercellular areas with brisk mitotic activity and 
pseudopallisading necrosis (C) consistent with spontaneous anaplastic transformation. Distinct 
anaplastic areas in upper fields (D), contained ATRX loss (E) and ultrabright foci on telomere 
FISH indicating ALT (arrow) (F), which were absent in the lower grade PA in lower fields (D-F), 
as well as in the PA precursor two years prior (not shown).  
 
Figure 3: Pilocytic astrocytoma with anaplasia (PA-A) with concurrent BRAF duplication, 
ALT and H3-K27M mutation (Case 9). This PA-A developed in the cerebellum of a 53-year-old 
woman during progression from a pre-existing PA. The precursor and the most recent resection 
had compact piloid areas with Rosenthal fibers and eosinophilic granular bodies (A). The 
anaplastic component had brisk mitotic activity (B) and pseudopallisading necrosis (C). 
Molecular alterations detected included ultrabright telomere FISH signals indicating ALT (D), 
ATRX loss (E), expression of H3-K27M mutant protein in almost 100% of neoplastic cells (F) 
and BRAF duplication (G). H3-K27M expression (H) and ATRX loss (not shown) were also 
present in a precursor 2 years prior, although the latter appeared to be present at a lower 
frequency in neoplastic cells. Next generation sequencing detected a AAG->ATG missense 
mutation in H3F3A at codon 27 Lysine (K) that was changed to Methionine (M) in all three H3-
K27M immunohistochemistry positive cases tested (I). 
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Figure 4: NF1-associated pilocytic astrocytoma with anaplasia (PA-A). PA-A developing in 
a patient with NF1 (A) and loss of ATRX expression (B). ALT-positive NF1-associated PA-A 
demonstrating large brown immunopositive telomeric foci through chromogenic in situ 
hybridization in >1% of cells corresponding to the ultrabright foci identified by telomere FISH 
indicative of ALT (C). ALT-negative PA-A had a tendency to have longer telomeres (brighter 
signals by telomere FISH) compared to internal non-neoplastic controls (arrow) (Case 4, 
Telomere FISH) (D). 
 
Figure 5: Relevant clinicopathologic features of pilocytic astrocytoma with anaplasia 
(PA-A). Relevant demographic, phenotypic and genetic features of pilocytic astrocytoma with 
anaplasia (PA-A) are summarized in A. Relevant features for precursors are summarized in B.  
 
Figure 6: Factors associated with overall and recurrence/progression-free survival in 
pilocytic astrocytoma with anaplasia (PA-A). Features associated with a worse outcome 
included the presence of necrosis, adult age (vs. pediatric), extent of resection (subtotal 
resection, STR, vs. gross total resection, GTR), and presence of ALT (Kaplan Meier curves, Log 
rank test).  
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Table 2. Summary of immunophenotypic and molecular features of pilocytic 
astrocytomas with anaplasia (PA-A). 
 
Alteration PA-A PA precursor  
ALT 25/36 (69%) 9/14 
ATRX (IHC) loss  20/35 (57%) 7/11 
IDH1 (R132H) 0/32 (0%) NA 
BRAF duplication 8/26 (31%) 8/14 
BRAF (V600E) 0/31 (0%)* NA 
NF1 status 12/36 (33%)
#
 3/19 
H3-K27M 5/32 (16%) 2/14 
CDKN2A 3/18 (17%)
&
 NA 
P53 (strong IHC) 6/17 (35%) NA 
 
ALT=alternative lengthening of telomeres, NF1=neurofibromatosis type 1 
*a single case had an activating mutation in BRAF (non V600E) by sequencing (BRAF p.D594G). 
# A total of 8 patients satisfied clinical criteria for NF1 while four additional patients demonstrated NF1 
mutations in their tumors by sequencing studies. 
& A total of 3 patients had homozygous deletion as tested by FISH (n=12), NGS (n=6), or both (n=1). 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 3. Clinicopathologic, molecular features and outcome in pilocytic 
astrocytoma with anaplasia (PA-A). 
Comparison N (%) Overall survival 
in days 
(mean+Std Error) 
Progression/ Recurrence 
free survival in days 
(mean+Std Error) 
P value1 
OS, PFS 
Resection 
GTR 
STR 
 
10 (45%) 
12 (55%) 
 
1724+587 
471+148 
 
1709+591 
293+137 
 
0.01, 0.0005 
Age 
Adult 
Pediatric 
 
11 (30%) 
25 (70%) 
 
565+125 
1703+597 
 
489+128 
1560+629 
 
0.03, 0.07 
Sex 
Male 
Female 
 
23 (64%) 
13 (36%) 
 
863+230 
954+438 
 
753+238 
885+443 
 
0.99, 092 
Anatomic Location 
Supratentorial 
Infratentorial 
 
12 (33%) 
24 (67%) 
 
1416+612 
683+153 
 
1042+540 
611+154 
 
0.15, 0.69 
Prior irradiation 
Yes 
No 
 
9 (26%) 
26 (74%) 
 
312+85 
1141+344 
 
269+57 
1047+354 
 
0.06, 0.18 
NF1 diagnosis 
Present 
Absent 
 
8 (22%) 
28 (78%) 
 
1123+562 
817+213 
 
842+595 
785+215 
 
0.40, 0.97 
PA precursor 
Preceding anaplasia 
De novo anaplasia 
 
15 (43%) 
20 (57%) 
 
442+194 
1140+321 
 
401+196 
1002+335 
 
0.02, 0.07 
Necrosis 
Present 
Absent 
 
24 (67%) 
12 (33%) 
 
584+213 
1463+409 
 
516+215 
1317+439 
 
0.009, 0.02 
Extent of anaplasia 
Focal  
Diffuse 
 
4 (11%) 
32 (89%) 
 
1016+924 
887+220 
 
534+468 
785+226 
 
0.83, 0.34 
ALT 
Positive 
Negative 
 
25 (69%) 
11 (31%) 
  
587+141 
1650+588 
 
492+143 
1553+609 
 
0.03, 0.02 
BRAF      
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Duplication 
No duplication 
8 (31%) 
18 (69%) 
610+270 
807+273 
588+272 
720+278 
0.88, 0.87 
ATRX expression 
Loss 
Preserved 
 
20 (57%) 
15 (43%) 
 
558+117 
1548+515 
 
448+119 
1468+529 
 
0.04, 0.03 
H3-K27M 
Present 
Absent 
 
5 (16%) 
27 (84%) 
 
780+291 
684+203 
 
669+313 
574+206 
 
0.55, 0.80 
1=Log Rank Test 
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